Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1331776-42-1

methyl 4-bromomethylcyclohexane-1-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1331776-42-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1331776-42-1 Structure

  • Basic information

    1. Product Name: methyl 4-bromomethylcyclohexane-1-carboxylate
    2. Synonyms:
    3. CAS NO:1331776-42-1
    4. Molecular Formula:
    5. Molecular Weight: 235.121
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1331776-42-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: methyl 4-bromomethylcyclohexane-1-carboxylate(CAS DataBase Reference)
    10. NIST Chemistry Reference: methyl 4-bromomethylcyclohexane-1-carboxylate(1331776-42-1)
    11. EPA Substance Registry System: methyl 4-bromomethylcyclohexane-1-carboxylate(1331776-42-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1331776-42-1(Hazardous Substances Data)

1331776-42-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1331776-42-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,1,7,7 and 6 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1331776-42:
(9*1)+(8*3)+(7*3)+(6*1)+(5*7)+(4*7)+(3*6)+(2*4)+(1*2)=151
151 % 10 = 1
So 1331776-42-1 is a valid CAS Registry Number.

1331776-42-1Downstream Products

1331776-42-1Relevant articles and documents

PROCESS FOR PREPARING TRANEXAMIC ACID

-

, (2021/06/11)

The present disclosure relates to a process for preparing tranexamic acid, the process comprising: a reacting a compound of Formula IV with at least one azidating agent to obtain a compound of Formula III, reducing the compound of Formula III to the compound of Formula I or hydrolyzing the compound of Formula III to the compound of Formula IIa, followed by reducing the compound of Formula IIa to the compound of Formula I or reducing the compound of Formula III to obtain a compound of Formula IIb, followed by hydrolyzing the compound of Formula IIb to obtain the compound of Formula I. The present disclosure also provides a single pot process for preparing Tranexamic acid of Formula I.

LACTAM COMPOUND AS FXR RECEPTOR AGONIST

-

Paragraph 0264, (2020/04/21)

Disclosed is a compound as shown in formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and the present invention relates to the use of same in the preparation of a drug for treating FXR-related diseases.

CHEMICAL COMPOUNDS

-

, (2020/12/01)

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS

-

Page/Page column 91, (2014/08/20)

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE

-

, (2008/06/13)

Novel diazepine derivatives which selectively inhibit adenosine monophosphate deaminase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1331776-42-1